The LMO2 oncogene causes a subset of human T cell acute lymphoblastic leukemias (T-ALL), including four cases that arose as adverse events in gene therapy trials. To investigate the cellular origin of LMO2-induced leukemia, we used cell fate mapping to study mice in which the Lmo2 gene was constitutively expressed in the thymus. Lmo2 induced self-renewal of committed T cells in the mice more than 8 months before the development of overt T-ALL. These self-renewing cells retained the capacity for T cell differentiation but expressed several genes typical of hematopoietic stem cells (HSCs), suggesting that Lmo2 might reactivate an HSC-specific transcriptional program. Forced expression of one such gene, Hhex, was sufficient to initiate self-renewal of thymocytes in vivo. Thus, Lmo2 promotes the self-renewal of preleukemic thymocytes, providing a mechanism by which committed T cells can then accumulate additional genetic mutations required for leukemic transformation. © 2010 American Association for the Advancement for Science. All Rights Reserved.
CITATION STYLE
McCormack, M. P., Young, L. F., Vasudevan, S., De Graaf, C. A., Codrington, R., Rabbitts, T. H., … Curtis, D. J. (2010). The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. Science, 327(5967), 879–883. https://doi.org/10.1126/science.1182378
Mendeley helps you to discover research relevant for your work.